Instruction 1(b).

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to Section 16. Form 4 or Form 5	STATEMENT OF CHA
obligations may continue. See	

NGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Moriarty John B					<u>A</u>	2. Issuer Name and Ticker or Trading Symbol ALEXION PHARMACEUTICALS INC [ALXN]								heck all appli Direct V Office	ationship of Reporting Pers all applicable) Director Officer (give title below)			ner pecify	
(Last) (First) (Middle) ALEXION PHARMACEUTICALS						3. Date of Earliest Transaction (Month/Day/Year) 10/06/2014								S	VP & Gen	neral C	Counsel		
352 KNOTTER DRIVE					4 1	If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable					
(Street) CHESHIRE CT 06410				- 4.1	4. II Amerianent, Date of Original Fliet (Montil/Day/Year)							Lir	ne) X Form)					
(City)	(S	tate)	(Zip)																
		Tab	le I - No	n-Deri\	vative	e Se	curit	ties Ac	quired,	Dis	posed o	f, or Be	neficia	lly Owned	l				
Date			2. Transaction Date (Month/Day/Year)		ar) E	2A. Deemed Execution Date, if any (Month/Day/Year)		Code (Transaction Code (Instr.		4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4		Benefic Owned	es ially Following	Form:	Direct Condinect Etr. 4)	7. Nature of Indirect Beneficial Ownership		
								Code	v	Amount	(A) or (D)	Price	Reporte Transac (Instr. 3	ction(s)			(Instr. 4)		
Common Stock, par value \$.0001 per share 10/06/				6/2014	2014			М		10,000	(1) A	\$95.	65 34	5 34,532		D			
Common Stock, par value \$.0001 per share 10/06/				6/2014	/2014					10,000	(1) D	\$179)(2) 24	24,532		D			
		-	Table II -								osed of, converti			y Owned					
	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deeme Execution if any (Month/Da	Date,	Code (Ins				6. Date Exercisable a Expiration Date (Month/Day/Year)		е	nd 7. Title and Amo of Securities Underlying Derivative Secu (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	illy	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercisa		Expiration Date	Title	Amount or Number of Shares						
Option to Purchase Common Stock	\$92.65	10/06/2014			М			10,000	12/10/20	13	12/10/2022	Common Stock, par value \$.0001	10,000	\$92.65	22,812	2	D		

Explanation of Responses:

- 1. The transactions reported by this Form 4 are made pursuant to the terms of a sales plan designed to meet the requirements of Rule 10b5-1(c)(1) of the Securities Exchange Act.
- 2. This transaction was executed in multiple trades through a broker-dealer at prices ranging from \$179.00 \$179.99. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price.

Remarks:

/s/ Michael Greco Attorney-in-**Fact**

** Signature of Reporting Person

Date

10/07/2014

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.